Inhibitors of Viral Protein Synthesis

Interferons are natural antivirals that bind to receptors on healthy host cells and trigger expression of interferon-stimulated genes. These genes induce synthesis of antiviral proteins including protein kinase R, oligoadenylate synthetase, and RNase L. When activated by viral double-stranded RNA, these proteins interrupt viral mRNA translation and degrade viral RNA, halting protein synthesis and limiting viral replication.

Protein kinase R is activated by viral double-stranded RNA during infection. Once active, it phosphorylates eukaryotic translation initiation factor 2 alpha, preventing the initiation of mRNA translation. This blocks synthesis of both viral and host proteins, effectively shutting down the translational machinery that viruses depend on to replicate.

Oligoadenylate synthetase is activated by viral double-stranded RNA and synthesizes short chains of adenylate molecules. These oligoadenylates activate RNase L, an enzyme that degrades viral and host mRNA. This degradation exacerbates the shutdown of protein synthesis and amplifies the antiviral state within infected cells.

Pegylated interferons are recombinant interferons created by attaching polyethylene glycol to interferon molecules. This modification enhances the stability and half-life of the interferon, allowing for less frequent dosing in clinical applications. Pegylated interferon combined with ribavirin was historically the standard therapy for chronic hepatitis C before newer direct-acting antivirals became available.

Viruses lack the cellular machinery required for protein synthesis and must hijack the host's translational apparatus to replicate. Since protein synthesis is indispensable for viral replication, host cells have evolved interferon-mediated defenses that target this critical process. By blocking translation, cells can effectively prevent viral propagation and promote infected cell death.

Recombinant interferons have diverse clinical applications. Interferon-alpha treats chronic hepatitis B and C, human papillomavirus-associated lesions, and Kaposi's sarcoma. Interferon-alpha also acts as an immunomodulatory agent in hematologic malignancies and melanoma. Interferon-beta is widely used to manage multiple sclerosis by reducing relapse frequency and delaying disability progression.

Interferon therapies are associated with flu-like symptoms, fatigue, depression, and hematologic abnormalities. These side effects may limit use in some patients despite the clinical benefits of interferons. However, their versatility across antiviral, oncologic, and immunologic domains underscores their clinical significance in treating multiple disease states.